Caterina Caputi

Caterina Caputi

Auto-generated profile, based on publicly available information

Caterina Caputi

Department of Human Neuroscience, Sapienza University of Rome, 00185 Rome, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
MMMario Mastrangelo
Mario Mastrangelo
FCFlavia Chiarotti
Flavia Chiarotti
LBLuana Berillo
Luana Berillo
CCCaterina Caputi
Caterina Caputi
Claudia CarducciClaudia Carducci
Claudia Carducci
VLVincenzo Leuzzi
Vincenzo Leuzzi

Verified
Journal Article
Open access
PDF file
LPLuca Pollini
Luca Pollini
SGSERENA GALOSI
SERENA GALOSI
MTManuela Tolve
Manuela Tolve
CCCaterina Caputi
Caterina Caputi
CCcarla carducci
carla carducci
VLVincenzo Leuzzi
Vincenzo Leuzzi
KCND3 encodes the voltage-gated potassium ion channel subfamily D member 3, a six trans-membrane protein (Kv4.3), involved in the transient outward K+ current. KCND3 defect causes both cardiological and neurological syndromes. From a neurological perspective, Kv4.3 defect has been associated to SCA type 19/22, a complex neurological disorder encompassing a wide spectrum of clinical features beside ataxia. To better define the phenotypic spectrum and course of KCND3-related neurological disorder, we review the clinical presentation and evolution in 68 reported cases. We delineated two main clinical phenotypes according to the age of onset. Neurodevelopmental disorder with epilepsy and/or movement disorders with ataxia later in the disease course characterized the early onset forms, while a prominent ataxic syndrome with possible cognitive decline, movement disorders, and peripheral neuropathy were observed in the late onset forms. Furthermore, we described a 37-year-old patient with a de novo KCND3 variant [c.901T>C (p.Ser301Pro)], previously reported in dbSNP as rs79821338, and a clinical phenotype paradigmatic of the early onset forms with neurodevelopmental disorder, epilepsy, parkinsonism-dystonia, and ataxia in adulthood, further expanding the clinical spectrum of this condition.

Verified
Journal Article
Open access
PDF file
DGDaniele Galatolo
Daniele Galatolo
GMGiovanna De Michele
Giovanna De Michele
Gabriella SilvestriGabriella Silvestri
Gabriella Silvestri
VLVincenzo Leuzzi
Vincenzo Leuzzi
CCCarlo Casali
Carlo Casali
FSFilippo M. Santorelli
Filippo M. Santorelli
The term hereditary ataxia (HA) refers to a heterogeneous group of neurological disorders with multiple genetic etiologies and a wide spectrum of ataxia-dominated phenotypes. Massive gene analysis in next-generation sequencing has entered the HA scenario, broadening our genetic and clinical knowledge of these conditions. In this study, we employed a targeted resequencing panel (TRP) in a large and highly heterogeneous cohort of 377 patients with a clinical diagnosis of HA, but no molecular diagnosis on routine genetic tests. We obtained a positive result (genetic diagnosis) in 33.2% of the patients, a rate significantly higher than those reported in similar studies employing TRP (average 19.4%), and in line with those performed using exome sequencing (ES, average 34.6%). Moreover, 15.6% of the patients had an uncertain molecular diagnosis. STUB1, PRKCG, and SPG7 were the most common causative genes. A comparison with published literature data showed that our panel would have identified 97% of the positive cases reported in previous TRP-based studies and 92% of those diagnosed by ES. Proper use of multigene panels, when combined with detailed phenotypic data, seems to be even more efficient than ES in clinical practice.

6 February 2013 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MMMario Mastrangelo
Mario Mastrangelo
CCCaterina Caputi
Caterina Caputi
SGSERENA GALOSI
SERENA GALOSI
MGMaria Teresa Giannini
Maria Teresa Giannini
VLVincenzo Leuzzi
Vincenzo Leuzzi

8 November 2021 in Human Mutation
Verified
Journal Article
Closed access
PDF file
SNSara Nuovo
Sara Nuovo
VBValentina Baglioni
Valentina Baglioni
RMRoberta De Mori
Roberta De Mori
STSilvia Tardivo
Silvia Tardivo
CCCaterina Caputi
Caterina Caputi
VLVincenzo Leuzzi
Vincenzo Leuzzi

1 April 2018 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
VLVincenzo Leuzzi
Vincenzo Leuzzi
DDDaniela D'AGnano
Daniela D'AGnano
MMMichele Menotta
Michele Menotta
CCCaterina Caputi
Caterina Caputi
LCLuciana Chessa
Luciana Chessa
Mauro MagnaniMauro Magnani
Mauro Magnani
Objective Ataxia-telangiectasia (AT) is a rare, severe, and ineluctably progressive multisystemic neurodegenerative disease. Variant AT phenotypes have been described in patients with mild- and late-onset neurologic deterioration and atypical features (dystonia and myoclonus). We report on the clinical characteristics and transcriptome profile of patients with a typical AT presentation and genotype who experienced an unexpected favorable course. Methods A 24-year-old woman developed, by the age of 3 years, all the classic symptoms of AT associated with increased alpha-fetoprotein levels, a compound AT-mutated (ATM) genotype with an inframe deletion c.2250G>A (p.Glu709_Lys750del42) and a missense mutation c.8122G>A (p.Asp2708Gln), and no residual ATM protein expression. By the age of 12 years, ataxia slowly disappeared, and a very mild choreic disorder was the only neurologic feature in adulthood. Brain MRI was normal. The blood transcriptome profile was assessed and compared with that of healthy controls and patients with the classic AT phenotype. Results The atypical clinical course of the patient was associated with a transitional transcriptome profile: while 90% of transcripts were expressed as in patients with the classic AT presentation, 10% of transcripts were expressed as in healthy controls. Conclusions The unexpected mild clinical outcome and transcriptome profile of this patient with AT suggest the existence of individual resilience to the altered ATM synthesis. Because of their possible prognostic and therapeutic implications, the identification of modifier factors affecting the phenotype would deserve further studies.